DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk - LARVOL DELTA

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study. (PubMed, Diabetes Obes Metab) - "iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and pharmacodynamics studies of different types of insulin with the canine euglycemic clamp. (PubMed, J Pharm Sci) - "Marked interspecies differences necessitated component-specific bidirectional correction for clinical dose extrapolation. This study confirms IDegAsp achieves complementary glycemic control via independently acting components without significant interference, providing robust nonclinical support and a reference framework for premixed insulin development."

Journal • PK/PD data • Diabetes • Hypoglycemia • Metabolic Disorders

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation. (PubMed, Front Public Health) - P3 | "Within the threshold of $40,344/QALY, the probability of iGlarLixi being cost-effective compared with IDegAsp was 83%. In individuals with type 2 diabetes inadequately controlled by oral antihyperglycemic agents, treatment with iGlarLixi is associated with superior long-term clinical outcomes and lower healthcare costs compared to IDegAsp in the Chinese healthcare setting."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies (ADA 2026) - "Introduction and Objective: Ph3 studies have compared iGlarLixi vs individual components (LixiLan-O-AP, LixiLan-L-CN) or IDegAsp (SoliD) in Asian PwT2D. This analysis showed consistent PPG and dTIR benefits over 24h with iGlarLixi vs comparators in Asian people with T2D."

Retrospective data • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. (PubMed, Diabetes Obes Metab) - "Once-daily iGlarLixi, injected before breakfast, was associated with improved HbA1c control and greater average 2-h PPG reductions compared with IDegAsp, regardless of injection time, in Chinese adults with T2D suboptimally controlled with OADs."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE (ISPOR 2026) - "iGlarLixi is a cost-effective option compared to iDegAsp for uncontrolled T2D in Turkiye,delivering additional life years and QALYs at an acceptable cost.Given the favorable cost-effectiveness of iGlarLixi in patients below the current BMI ≥35 reimbursement cutoff,policymakers could broaden their perspective in the reimbursement restrictions to enhance patient access to newer treatments"

HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China (clinicaltrials.gov) - P3 | N=414 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis. (PubMed, Diabetes Metab Syndr Obes) - "To evaluate the efficacy, safety, and patient satisfaction of transitioning from CSII to three treatment regimens: insulin degludec (IDeg), insulin degludec/insulin aspart (IDegAsp), or insulin degludec and liraglutide (IDegLira). All three regimens enabled a smooth transition after CSII therapy. IDegAsp and IDegLira demonstrated superior glycemic control and reduced variability compared to IDeg. IDegLira was more convenient and associated with higher patient satisfaction."

Journal • Retrospective data • Diabetes • Fatigue • Hypoglycemia • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis. (PubMed, J Diabetes Investig) - "Among the three fixed-ratio combination products, IDegLira appears most effective for glycemic control (in terms of HbA1c and FPG reduction), whereas IDegAsp demonstrates the best safety profile regarding incidence of TEAEs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

IMPACT OF TIME OF INJECTION COMPARING IGLARLIXI VS IDEGASP IN CHINESE PEOPLE WITH T2D: EXPLORATORY ANALYSIS OF SOLID STUDY (ATTD 2026) - P3 | "iGlarLixi confirmed better glycaemic control and body weight benefits with lower insulin doses and less hypoglycaemia risk vs IDegAsp regardless of IDegAsp injection time. Funded by Sanofi. Previously presented at ADA and EASD."

Hypoglycemia • Type 2 Diabetes Mellitus

EFFICACY OF IGLARLIXI VERSUS IDEGASP IN CHINESE PEOPLE WITH T2D BY HBA1C TARGET AT END-OF-TREATMENT AND BASELINE POSTPRANDIAL GLUCOSE: A POST-HOC ANALYSIS OF SOLI-D STUDY (ATTD 2026) - P3 | "This post-hoc analysis assessed efficacy and safety of iGlarLixi by HbA1c target achievement and number of participants achieving postprandial glucose (PPG) target at end-of-treatment (EOT). In Soli-D (NCT05413369), Phase-3, 24-week study, insulin-naïve Chinese-adults were randomised 1:1 to receive either iGlarLixi or IDegAsp, with metformin±SGLT-2i. More participants receiving iGlarLixi than IDegAsp achieved HbA1c, PPG targets, body-weight benefit and fewer hypoglycaemic events at EOT. Moreover, in people not achieving HbA1c ≤7%, iGlarLixi could be better titrated as the number of hypoglycaemia events was low."

Clinical • Retrospective data • Hypoglycemia • Type 2 Diabetes Mellitus

NN1535-8377: A research study to see how weekly IcoSema controls blood sugar levels when compared with daily insulin degludec/insulin aspart (IDegAsp) in people with poorly controlled type 2 diabetes (COMBINE 5) (clinicaltrialsregister.eu) - P2/3 | N=72 | Completed | Sponsor: Novo Nordisk A/S

New P2/3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (clinicaltrials.gov) - P=N/A | N=218 | Completed | Sponsor: Beijing Hospital | Not yet recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2023 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of insulin degludec/aspart in patients with type 2 and type 1 diabetes mellitus: real-world evidence from Indonesia. (PubMed, Front Endocrinol (Lausanne)) - "Real-world studies on insulin degludec/aspart (IDegAsp) have been conducted in some Southeast Asian populations; however, data specific to Indonesia remain limited. IDegAsp demonstrated sustained glycemic improvement at 3-, 6-, and 12-months follow-ups with a favorable safety profile over one year, in both T1DM and T2DM populations in Indonesia. These findings support its utility in routine clinical practice, particularly among patients with unmet glycemic targets or complex treatment needs."

HEOR • Journal • Real-world evidence • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Early Glycemic Control With iGlarLixi Versus IDegAsp in Chinese Adults With Type 2 Diabetes: A Post Hoc Analysis of the Soli-D Study. (PubMed, J Diabetes) - No abstract available

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study. (PubMed, J Diabetes Investig) - "HS-IDegAsp demonstrated comparable efficacy and safety to NN-IDegAsp during the 24-week treatment period in Chinese patients with inadequately controlled T2DM previously treated on once- or twice-daily premixed or basal insulin, with or without OADs."

Journal • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study. (PubMed, Diabetes Obes Metab) - "iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C-peptide or HOMA-β levels, in Chinese people with uncontrolled T2D on OADs."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=324 | Not yet recruiting | Sponsor: Yanbing Li

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of time of injection on the efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes: exploratory analysis of the Soli-D study (EASD 2025) - P3 | "Clinical Trial Registration Number: NCT05413369 Background and aims: The Soli-D study demonstrated better glycaemic control and body weight (BW) benefits with iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, vs a fixed-ratio of insulin degludec + insulin aspart (IDegAsp) at 24 weeks in Chinese adults with type 2 diabetes (T2D) suboptimally controlled with glucose-lowering oral agents (OADs)... iGlarLixi injected before breakfast demonstrated better HbA1c and average 2-h PPG control compared with IDegAsp in T2D Chinese adults suboptimally controlled with OADs, regardless of IDegAsp injection time, while also providing better overall glycaemic control and BW benefits with lower insulin doses and less hypoglycaemia risk."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial. (PubMed, Diabetes Metab J) - "The HbA1c benefit of IDegAsp over IGlar was associated with a low glucagon-like peptide-1 (GLP-1) ratio at 30 minutes relative to baseline (r=0.301, P=0.040), while not with glucose-dependent insulinotropic polypeptide. The greater reduction in HbA1c achieved with IDegAsp compared to IGlar in individuals with T2DM was associated with an impaired GLP-1 response, facilitating personalized insulin therapy."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes. (PubMed, Diabetol Metab Syndr) - "Initiating or switching to the IDegAsp reusable pen with the insulin cartridge system in a real-world population of people with T2D in Türkiye was associated with improved or maintained glycemic control."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time-in-ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli-D study. (PubMed, Diabetes Obes Metab) - No abstract available

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study (ADA 2025) - P3 | "iGlarLixi confirmed better glycemic control and body weight benefits with lower insulin doses and less hypoglycemia risk vs IDegAsp regardless of IDegAsp injection time."

Late-breaking abstract • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study (ADA 2025) - "In this post hoc analysis, regardless of baseline HbA1c level, iGlarLixi demonstrated better clinical outcomes vs IDegAsp. Results from this analysis are consistent with primary results reported previously."

Clinical • Retrospective data • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus